Form 4: X4 Pharmaceuticals Chief Medical Officer Receives 850,000 Restricted Stock Units

Christophe Arbet-Engels, Chief Medical Officer of X4 Pharmaceuticals, was granted 850,000 restricted stock units under the company's equity incentive plan.

Summary

• On February 12, 2025, Christophe Arbet-Engels, the Chief Medical Officer of X4 Pharmaceuticals, received a grant of 850,000 restricted stock units (RSUs).
• These RSUs were granted under the Issuer's Amended and Restated 2017 Equity Incentive Plan.
• Each RSU represents the right to receive one share of common stock on the applicable vesting date.
• No amount was paid upon the grant of the RSUs.
• The RSUs vest in three equal annual installments on February 12, 2026, February 12, 2027, and February 12, 2028.
• Vesting is contingent upon Mr. Arbet-Engels continuing to be an employee of X4 Pharmaceuticals through each vesting date.
• Following this transaction, Mr. Arbet-Engels beneficially owns 864,207 shares of common stock.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting stability and alignment of interests. It's a neutral to slightly positive event.

Positives

• The grant of restricted stock units aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company over the next three years.

Risks

• The value of the restricted stock units is dependent on the future performance of X4 Pharmaceuticals' stock.
• If Mr. Arbet-Engels leaves the company before the vesting dates, he will forfeit the unvested RSUs.

Future Outlook

The vesting of the restricted stock units is contingent upon the Reporting Person continuing to provide service as an employee of the Issuer through such date.

Industry Context

Grants of restricted stock units are a common practice in the pharmaceutical industry to incentivize and retain key executives.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates